The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line Raffaele PezzaniBeatrice RubinMarco Boscaro PRECLINICAL STUDIES 14 May 2016 Pages: 531 - 540
In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118 Eduardo J. SalustianoMatheus L. DumasVivian M. Rumjanek PRECLINICAL STUDIES 18 May 2016 Pages: 541 - 551
Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report Magdalena KusaczukRafał KrętowskiMarzanna Cechowska-Pasko PRECLINICAL STUDIES Open access 29 July 2016 Pages: 552 - 564
Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors Cynthia M. NijenhuisEdward HellriegelJan H. M. Schellens PHASE I STUDIES Open access 25 May 2016 Pages: 565 - 574
Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001) Amy PrawiraIrene Brana-GarciaAaron R Hansen PHASE I STUDIES 11 June 2016 Pages: 575 - 583
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies Kiyotaka YohToshihiko DoiKazunori Uenaka PHASE I STUDIES Open access 01 September 2016 Pages: 584 - 595
Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors Hidenori MizugakiNoboru YamamotoToshiaki Takahashi PHASE I STUDIES Open access 01 July 2016 Pages: 596 - 603
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors Lee S. RosenPatricia LoRussoBranimir I. Sikic PHASE I STUDIES 16 July 2016 Pages: 604 - 613
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia Karen W. L. YeeHsiao-Wei T. ChenMark D. Minden PHASE I STUDIES 12 July 2016 Pages: 614 - 624
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer Giorgio ScagliottiJin Hyoung KangMary Pinder-Schenck PHASE II STUDIES 27 June 2016 Pages: 625 - 635
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites Naminatsu TakaharaHiroyuki IsayamaKazuhiko Koike PHASE II STUDIES 23 June 2016 Pages: 636 - 642
The renal effects of ALK inhibitors Hassan IzzedineRania Kheder El-FekihMark A. Perazella REVIEW 29 July 2016 Pages: 643 - 649
Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy Farzan KianersiHeshmatollah GhanbariAfsaneh Naderi Beni SHORT REPORT 02 June 2016 Pages: 650 - 653
Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors Noura BenslamaJulien BollardThomas Walter SHORT REPORT 26 May 2016 Pages: 654 - 662
Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine–induced apoptosis in neuroblastoma cells Jennifer C. LennonStefania ButiniDaniela M. Zisterer SHORT REPORT 22 June 2016 Pages: 663 - 676